These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9402172)

  • 21. c-myc hypermutation is ongoing in endemic, but not all Burkitt's lymphoma.
    Johnston JM; Yu MT; Carroll WL
    Blood; 1991 Nov; 78(9):2419-25. PubMed ID: 1932754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes.
    Cinti C; Leoncini L; Nyongo A; Ferrari F; Lazzi S; Bellan C; Vatti R; Zamparelli A; Cevenini G; Tosi GM; Claudio PP; Maraldi NM; Tosi P; Giordano A
    Am J Pathol; 2000 Mar; 156(3):751-60. PubMed ID: 10702389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A translocation t(8;14) and c-myc gene rearrangement associated with the histological transformation of B-cell acute lymphocytic leukemia (FAB-L2) into Burkitt's type (FAB-L3) leukemia.
    Masauzi N; Kasai M; Suzuki G; Kobayashi N; Ohizumi H; Ogasawara M; Kiyama Y; Naohara T; Saitoh M; Higa T; Tanaka J; Hashino S; Imamura M; Asaka M
    Leuk Lymphoma; 1997 Oct; 27(3-4):357-63. PubMed ID: 9402334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatic mutation of the 5' noncoding region of the BCL-6 gene is associated with intraclonal diversity and clonal selection in histological transformation of follicular lymphoma.
    Szereday Z; Csernus B; Nagy M; László T; Warnke RA; Matolcsy A
    Am J Pathol; 2000 Mar; 156(3):1017-24. PubMed ID: 10702417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective.
    Gaidano G; Pastore C; Volpe G
    Haematologica; 1995; 80(5):454-72. PubMed ID: 8566891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas.
    Gaidano G; Volpe G; Pastore C; Chiarle R; Capello D; Gloghini A; Perissinotto E; Savinelli F; Bosco M; Mazza U; Pileri S; Palestro G; Carbone A; Saglio G
    Am J Hematol; 1997 Dec; 56(4):206-13. PubMed ID: 9395180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
    Bemark M; Neuberger MS
    Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis.
    Busch K; Borkhardt A; Wössmann W; Reiter A; Harbott J
    Haematologica; 2004 Jul; 89(7):818-25. PubMed ID: 15257933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas.
    Bertrand P; Bastard C; Maingonnat C; Jardin F; Maisonneuve C; Courel MN; Ruminy P; Picquenot JM; Tilly H
    Leukemia; 2007 Mar; 21(3):515-23. PubMed ID: 17230227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in the coding region of c-myc occur independently of mutations in the regulatory regions and are predominantly associated with myc/Ig translocation.
    Bhatia K; Spangler G; Hamdy N; Neri A; Brubaker G; Levin A; Magrath I
    Curr Top Microbiol Immunol; 1995; 194():389-98. PubMed ID: 7895514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype.
    Gaidano G; Lo Coco F; Ye BH; Shibata D; Levine AM; Knowles DM; Dalla-Favera R
    Blood; 1994 Jul; 84(2):397-402. PubMed ID: 8025268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.
    Madisen L; Groudine M
    Genes Dev; 1994 Sep; 8(18):2212-26. PubMed ID: 7958890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment of the novel B acute lymphoblastic leukemia (FAB L3) cell line KHM-10B with a 13q34 abnormality and constitutive expression of c-myc and max during cell cycle.
    Sonoki T; Matsuzaki H; Miyamoto K; Taniwaki M; Yoshino T; Hata H; Yoshida M; Matsuno F; Nagasaki A; Kuribayashi N
    Leukemia; 1995 Dec; 9(12):2093-9. PubMed ID: 8609722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CT-element of the c-myc gene does not predispose to chromosomal breakpoints in Burkitt's lymphoma.
    Weber A; Gutierrez MI; Levens D
    Cell Oncol; 2006; 28(1-2):31-5. PubMed ID: 16675879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
    Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
    Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chromosome translocations and Epstein-Barr virus in Burkitt's lymphoma].
    Bornkamm GW; Polack A; Eick D; Berger R; Lenoir GM
    Onkologie; 1987 Aug; 10(4):196-204. PubMed ID: 2823199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma.
    Yano T; Sander CA; Clark HM; Dolezal MV; Jaffe ES; Raffeld M
    Oncogene; 1993 Oct; 8(10):2741-8. PubMed ID: 8397370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular kinetic and phenotypic heterogeneity in and among Burkitt's and Burkitt-like lymphomas.
    Spina D; Leoncini L; Megha T; Gallorini M; Disanto A; Tosi P; Abinya O; Nyong'O A; Pileri S; Kraft R; Laissue JA; Cottier H
    J Pathol; 1997 Jun; 182(2):145-50. PubMed ID: 9274523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group.
    Davi F; Delecluse HJ; Guiet P; Gabarre J; Fayon A; Gentilhomme O; Felman P; Bayle C; Berger F; Audouin J; Bryon PA; Diebold J; Raphaël M
    J Clin Oncol; 1998 Dec; 16(12):3788-95. PubMed ID: 9850023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
    Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
    Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.